OBI PHARMA, INC.
- Country
- 🇨🇳China
- Ownership
- Public, Private
- Established
- 2002-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.obi.fr
Clinical Trials
14
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- OBI Pharma, Inc
- Target Recruit Count
- 117
- Registration Number
- NCT06480240
- Locations
- 🇺🇸
California Clinical Trials Medical Group (CCTMG), Glendale, California, United States
🇺🇸Scripps Green Hospital, La Jolla, California, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: 30 μg OBI-833/100 μg OBI-821
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- OBI Pharma, Inc
- Target Recruit Count
- 60
- Registration Number
- NCT05442060
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Beitou District, Taiwan
🇨🇳National Taiwan University Cancer Center, Taipei, Da'an Dist., Taiwan
🇨🇳Linkou Chang Gung Memorial Hospital, Taoyuan, Guishan Dist., Taiwan
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- OBI Pharma, Inc
- Target Recruit Count
- 44
- Registration Number
- NCT04084366
- Locations
- 🇺🇸
Scripps MD Anderson Cancer Center, La Jolla, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸West Cancer Center, Germantown, Tennessee, United States
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- OBI Pharma, Inc
- Target Recruit Count
- 68
- Registration Number
- NCT03592264
- Locations
- 🇺🇸
Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
- Conditions
- Metastatic Solid TumorsLocally Advanced Solid Tumors
- Interventions
- Device: Globo H IHC Assay
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- OBI Pharma, Inc
- Target Recruit Count
- 54
- Registration Number
- NCT03573544
- Locations
- 🇺🇸
Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
- Prev
- 1
- 2
- Next